Intratumoral CD103
CD103
CD8
head and neck squamous cell carcinoma
neoadjuvant chemoimmunotherapy
predictive marker
tumor-infiltrating lymphocyte
Journal
Cancer communications (London, England)
ISSN: 2523-3548
Titre abrégé: Cancer Commun (Lond)
Pays: United States
ID NLM: 101723675
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
19
06
2023
received:
03
03
2023
accepted:
22
08
2023
medline:
12
10
2023
pubmed:
2
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
Immune cell heterogenicity is known to determine the therapeutic response to cancer progression. Neoadjuvant chemoimmunotherapy (NACI) has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism behind this clinical response is unknown. The efficacy of NACI needs to be potentiated by identifying accurate biomarkers to predict clinical responses. Here, we attempted to identify molecules predicting NACI response in advanced HNSCC. We performed combined single-cell RNA sequencing (scRNA-seq) and multiplex immunofluorescence (mIHC) staining with tumor samples derived from NACI-treated HNSCC patients to identify a new tumor-infiltrating cell (TIL) subtype, CD103 We established intratumoral CD103 Our study highlights the impact of intratumoral CD103
Sections du résumé
BACKGROUND
Immune cell heterogenicity is known to determine the therapeutic response to cancer progression. Neoadjuvant chemoimmunotherapy (NACI) has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma (HNSCC), but the underlying mechanism behind this clinical response is unknown. The efficacy of NACI needs to be potentiated by identifying accurate biomarkers to predict clinical responses. Here, we attempted to identify molecules predicting NACI response in advanced HNSCC.
METHODS
We performed combined single-cell RNA sequencing (scRNA-seq) and multiplex immunofluorescence (mIHC) staining with tumor samples derived from NACI-treated HNSCC patients to identify a new tumor-infiltrating cell (TIL) subtype, CD103
RESULTS
We established intratumoral CD103
CONCLUSIONS
Our study highlights the impact of intratumoral CD103
Identifiants
pubmed: 37658605
doi: 10.1002/cac2.12480
pmc: PMC10565384
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1163Informations de copyright
© 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.
Références
J Clin Invest. 2022 Sep 15;132(18):
pubmed: 35727629
Nat Commun. 2021 Dec 22;12(1):7348
pubmed: 34937871
Nat Cancer. 2022 Jan;3(1):108-121
pubmed: 35121991
Nat Commun. 2022 Aug 18;13(1):4851
pubmed: 35982052
Pharmacol Res. 2020 Sep;159:104876
pubmed: 32422340
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152
pubmed: 32665297
Ann Oncol. 2018 Aug 1;29(8):1853-1860
pubmed: 29982279
Cell. 2021 May 27;184(11):2988-3005.e16
pubmed: 34019793
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Cancer Commun (Lond). 2021 Oct;41(10):1037-1048
pubmed: 34288593
Cell Rep Med. 2020 Oct 20;1(7):100127
pubmed: 33205076
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Nat Immunol. 2018 Jun;19(6):538-546
pubmed: 29777219
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
Nat Commun. 2022 Apr 1;13(1):1742
pubmed: 35365629
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Nat Commun. 2021 Feb 16;12(1):1047
pubmed: 33594075
Front Oncol. 2022 Oct 21;12:1012058
pubmed: 36338744
Cell. 2022 Mar 31;185(7):1189-1207.e25
pubmed: 35325594
Nat Commun. 2022 Jul 6;13(1):3882
pubmed: 35794100
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827905
Cancer Immunol Immunother. 2022 Jan;71(1):121-136
pubmed: 34028567
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
Front Immunol. 2018 Aug 15;9:1904
pubmed: 30158938
Cancer Commun (Lond). 2021 Sep;41(9):803-829
pubmed: 34165252
N Engl J Med. 2020 Jun 25;382(26):e108
pubmed: 32579835
Front Immunol. 2022 Jan 25;12:798424
pubmed: 35145511
FASEB J. 2015 Nov;29(11):4497-511
pubmed: 26139098
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
FEBS Lett. 2009 Sep 3;583(17):2749-57
pubmed: 19665027
Cancer Commun (Lond). 2023 Oct;43(10):1143-1163
pubmed: 37658605
Nat Rev Cancer. 2019 Apr;19(4):215-227
pubmed: 30867580
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Trends Immunol. 2022 Jul;43(7):523-545
pubmed: 35624021
Oral Oncol. 2022 Dec;135:106226
pubmed: 36323071
Nat Cancer. 2022 Sep;3(9):1123-1136
pubmed: 36138134
Nat Commun. 2019 Feb 4;10(1):567
pubmed: 30718505
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancer Immunol Res. 2020 Apr;8(4):479-492
pubmed: 32075801
Cell Death Dis. 2022 Feb 4;13(2):117
pubmed: 35121729
Front Oncol. 2022 Mar 08;12:782058
pubmed: 35345446
Clin Cancer Res. 2022 Aug 2;28(15):3268-3276
pubmed: 35766967
Nat Cancer. 2022 Nov;3(11):1300-1317
pubmed: 36434392
Cell. 2020 Aug 20;182(4):872-885.e19
pubmed: 32783915
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8
pubmed: 34653365
Cancer Immunol Immunother. 2021 Jul;70(7):1907-1915
pubmed: 33398391
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
JAMA Oncol. 2020 Oct 1;6(10):1563-1570
pubmed: 32852531
Cancer Cell. 2022 May 9;40(5):545-557.e13
pubmed: 35427494
Nat Rev Cancer. 2022 Nov;22(11):640-656
pubmed: 36109621
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259